BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)
Shots:
- BMS reported topline data from 2 P-III studies of Sotyktu vs PBO for active PsA, with POETYK PsA-1 involving ~670 bDMARD-naïve patients while POETYK PsA-2 involving ~730 patients who were bDMARD-naïve and treated with prior TNFα inhibitor
- Both the studies achieved 1 & 2EPs, showing greater no. of Sotyktu-treated patients achieving ACR20 at wk.16 along with a safety aligning with prior trials. Detailed results will be presented at future conferences
- Sotyktu (oral) is a selective TYK2 inhibitor with a unique allosteric mechanism, targeting IL-23, IL-12, and Type 1 IFNs. It represents a new class of small molecules and does not inhibit JAK1, JAK2, or JAK3 at therapeutic doses
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
